1- World Health organisation:
WHO/TDR (15.01.1997 – 04.07.1999) On-site Clinical Trial Monitor and Member of Data & Safety Monitoring Board for a randomised, double-blind, BCG-controlled trial in Sudan (Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis): Lancet. 2000 Nov 4; 356 (9241):1565-9.
WHO/TDR Temporary advisor for a miltefosine as first line drug treatment for visceral leishmaniasis clinical trial, AHRI, Addis Ababa, Ethiopia (March-Nov. 2003).
WHO/TDR Product Development Team (PDT) Meeting on Future Plans for leishmaniasis vaccines development (consultant), department of Clinical Pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan, 21-22.02.2003. WHO/TDR Temporary advisor for a clinical trial of Safety, tolerability and Pharmacokinetic studies on the combination therapy of Praziquantel + Oxamniquine (PZQ + OXA). Study on normal Volunteers, the Academy of Health Sciences and Technology, Khartoum, Sudan (Feb. 2006 ongoing). Invited as an expert for a consultative meeting on the development of therapeutic vaccines for post kala-azar dermal leishmaniasis (PKDL), W4115, WHO/TDR Casai, Geneva 8-9 December 2005 (Published in Kinetoplastid, Ghalib H and Modabber F, 2007), presented a talk about immunochemotherapy of PKDL studies in Sudan. Invited as an expert for a consultative meeting on the development of therapeutic vaccines for post kala-azar dermal leishmaniasis (PKDL), W4115, WHO/TDR Casai, Geneva 7- 8 August 2006. Developing a protocol for immunochemotherapy of PKDL using second generation vaccine (Leish 111f). Consultant, member of the World Health OrganizatiOrganization Expert committee on Leishmaniasis control, Geneva (2009-ongoing). 2. Sudan Facilitator, Seminar on Health Research Ethics, Organised by the Institute of Endemic Diseases, University of Khartoum, Presented a talk about the Concept of Good Clinical Practice (GCP), 23.08.2001.
Advisor, Workshop on Developing a National Policy on Leishmaniasis Control in the Sudan. (Federal Ministry of Health, Sudan; WHO; MSF-Holland) Khartoum, Sudan, 23rd – 24th February 2003.
Facilitator, ethics in clinical research, Federal Ministry of health, Faculty of medicine and the Institute of Endemic Diseases, University of Khartoum, Sudan, 22-26.06.06.
Organizer and Facilitator, ethics of health research training for community lay people, Kassab site, Gedarif State, Eastern Sudan, 4-6 June 2007. Facilitator, Best Practices in Ethical Review, a workshop for members of Ethics Committees in Sudan organized by Tropical Medicine Research Institute and HAT platform (DNDi), Khartoum, Sudan 24-26.7.2007. Speaker, HAT Platform annual meeting, 27-29.11.2007, presented a talk about LEAP experience, Grand Villa Holiday, Khartoum, Sudan. Facilitator, Winter course of Life Sciences on Immunology organized by the School of Life Sciences, faculty of Science and Technology, Alneelain University in collaboration with the International Union of Immunological societies & The Federation of African Immunological Societies, 5-10 January 2008.
3. Drugs for Neglected Diseases initiatives (DNDi) Consultant for DNDi (Drugs for neglected diseases initiatives) 2nd LEAP (Leishmaniasis East Africa Platform) meeting on Finding a new drug or combination of drugs for treatment of visceral leishmaniasis, Khartoum, Sudan 25-26.08.2003. Consultant for DNDi (Drugs for neglected diseases initiatives) the 3rd
Consultant, Regional DNDi (Drugs for neglected diseases initiatives) the 4th LEAP (Leishmaniasis East Africa Platform) meeting on preparation for A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, KEMRI, Kenya, 8- LEAP (Leishmaniasis East Africa Platform) meeting on preparation for a multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Addis Ababa, Ethipia 12-13.05.2004.
13
9.10.2004. Consultant for DNDi (Drugs for neglected diseases initiatives) 5th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Khartoum, Sudan 11-12.03.2005. Consultant, 1st DNDi (Drugs for neglected diseases initiatives) consultative meeting on intrim analysis of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, KEMRI, Kenya, 20-21.06.2005. Consultant, regional DNDi (Drugs for neglected diseases initiatives) 6th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Addis Ababa, Ethiopia 11-12.02.2006
Consultant, 2nd DNDi consultative meeting on the pharmacokinetics sub-study analysis as part of the multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis,8-9.06.06, KEMRI, Nairobi, Kenya. Clinical Trial Monitoring expert, DNDi clinical Trials monitors meeting 5-6.02.2007, Nairobi, Kenya. Consultant, regional DNDi (Drugs for neglected diseases initiatives) 8th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Kampala, Uganda 15-16.03.2007.
Consultant, regional DNDi (Drugs for neglected diseases initiatives) 9th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, London, United Kingdom, 09-10.09.2007. Consultant, regional DNDi (Drugs for neglected diseases initiatives) 10th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Khartoum, Sudan 19-20.02.2008
DNDi PIs meeting to discuss the ongoing research project (LEAP 0104B) and future research projects of combination therapies for treatment of visceral leishmaniaiasis, KEMRI, Nairobi, Kneya, 08-09.05.2008. Trainer for DNDi Clinical Trial site staff at Amudat Hospital, Uganda. Training for one week on Diagnosis and management of patients with visceral leishmaniasis. The training was composed of bedside and laboratory clinical teaching to prepare the site for joining the LEAP 0104B project, Amudat hospital, Uganda, 11-17.07.2008. Consultant, regional DNDi (Drugs for neglected diseases initiatives) 11th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Addis Ababa, Ethiopia, 28-29.08.2008
4. Others Participant, invited by the DNDi (Drugs for neglected diseases initiatives) the 11th
Participant, The centenary meeting of the Royal Society of Tropical Medicine 13- parasitology congress, Glasgow, United Kingdom, 6-11.08.06.
15
15.9.2007, London, UK.
Participant, Dormy II meeting 24-27.9.2007 functional genomic of leishmania vaccines, York University, UK. Speaker, 59th American Society of Tropical Medicine & Hygiene; Presented the results of the LEAP0104B clinical trial which concluded that a 17-day course of sodium stibogluconate in combination with paromomycin is a suitable first line treatment for treatment of visceral leishmaniasis in East Africa, 3-7.11.2010. Panelist, 3rd
1. Khalil EAG, Kamil AA, Mukhtar MM, Musa AM, Ibrahim ME, Modabber F, Sacks D, Smith PG, Zicker F and EL-Hassan AM. Intradermal injection of Alum-adsorbed ALM vaccine Plus BCG promotes induction of Th1 cytokines in healthy volunteers. Oral presentation; Oxford 2000, New Challenges in Tropical Medicine and Parasitology. stakeholders meeting of DNDi, improving access to treatment of visceral leishmaniasis in East Africa, New Delhi, 3.12.2010.
Memberships of Learned Societies (year of entry) Sudanese Leishmaniasis Research Group (1997, Institute of Endemic Diseases, U. of Khartoum). Tuberculosis Research Group (2000, Institute of Endemic Diseases, U. of Khartoum). Sudanese Clinical biology society (2003). Leishmaniasis East Africa Platform (LEAP) 2003. Sudanese Society of Immunologist (2008 to date)
